Souhaitez-vous accéder aux communiqués récents ?

LOUISVILLE, Ky., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by SpringWorks Therapeutics, Inc....

Pune, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Knee Replacement Market Size & Growth Analysis: “According to SNS Insider, The Knee Replacement Market size was valued at USD 10.61 billion in 2023 and...

SHENZHEN, CHINA, Feb. 14, 2025 (GLOBE NEWSWIRE) --  In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings...

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as...

THE ANNOUNCEMENT on the holding of the extraordinary general meeting of a joint stock company: ZTS Sabinov, a. s., registered seat: Hollého 27, 083 30 Sabinov, ID No.: 00 590 797, registered...

ReversingLabs revealed a novel ML malware attack technique on the AI community Hugging Face. Dubbed “nullifAI,” it impacted 2 ML models Hugging Face host.

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high...

Santa Clara, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The second annual Iceberg Summit, sanctioned by the Apache Software Foundation (ASF) and overseen by the Apache Iceberg Project Management...

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management Essentially all...

- Primary endpoint achieved by both DURAVYU doses (1.34mg and 2.7mg) with extended time to first supplemental injection versus aflibercept control – - DURAVYU 2.7mg demonstrated an early and...